Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

U.S. News

FDA Halts Reviews of Pending Ranbaxy Applications, Cites Fraudulent Lab Tests

February 27, 2009

FDA on Wednesday halted its review of all pending applications from India's Ranbaxy Laboratories, citing fraudulent laboratory tests dating back to 2006, the Washington Post reports. This is the second sanction against Ranbaxy in six months -- officials in September 2008 blocked the company from importing some drugs made at its plants in Dewas and Paonta Sahib (Layton, Washington Post, 2/26). Ranbaxy manufactures generic antiretroviral drugs used in the U.S. and in the President's Emergency Plan for AIDS Relief, as well as other generic drugs (Kaiser Daily HIV/AIDS Report, 9/17/08).

According to the Post, FDA investigators said the current problems concern the company's plant in Paonta Sahib, which has produced 25 FDA-approved drugs. Most of those drugs are not believed to be carried in U.S. pharmacies, and FDA is not seeking a recall on the medications because regulators do not believe the drugs post a health risk. The affected drugs include medications for high cholesterol and an antihistamine, but FDA would not provide a specific list, the Post reports. Deborah Autor, director of compliance at FDA, said there is "no concern about the safety or efficacy of Ranbaxy's drugs on the U.S. market." However, federal officials said they were concerned enough by their investigation into the plant that they decided to stop approvals of any new or pending applications for Ranbaxy's drugs. If Ranbaxy improves its manufacturing process the agency will resume approvals, Autor said. Douglas Throckmorton, deputy director of FDA's Center for Drug Evaluation and Research, said patients using the drugs should not stop their treatment (Washington Post, 2/26).

According to the Newark Star-Ledger, FDA said the company did not properly test the shelf-life and other safety measures of its drugs and then lied about the results. Ranbaxy said in a statement that it will "continue to cooperate with" FDA and that "[n]o effort or action will be spared to protect key (new drug applications) from Paonta Sahib" (Todd, Newark Star-Ledger, 2/26).

Back to other news for February 2009

Advertisement


Reprinted with permission from kaisernetwork.org. You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/hiv. The Kaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2009 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
 
See Also
More on the FDA Drug Approval Process and Other Regulatory Issues
Advertisement:
Find out how a Walgreens specially trained pharmacist can help you

Tools
 

Advertisement